Publications
Detailed Information
High-concentration (20 μg g−1) tacalcitol ointment in the treatment of facial psoriasis: an 8-week open-label clinical trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, J. W. | - |
dc.contributor.author | Choi, J-W. | - |
dc.contributor.author | Kwon, I-H. | - |
dc.contributor.author | Youn, J-I. | - |
dc.date.accessioned | 2012-07-04T01:15:58Z | - |
dc.date.available | 2012-07-04T01:15:58Z | - |
dc.date.issued | 2010-06 | - |
dc.identifier.citation | BRITISH JOURNAL OF DERMATOLOGY; Vol.162(6); 1359-1364 | ko_KR |
dc.identifier.issn | 0007-0963 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78357 | - |
dc.description.abstract | Background Facial psoriasis gives rise to considerable concern because of associated cosmetic problems and psychosocial distress. It requires a treatment approach other than topical corticosteroids, which bear a risk of cutaneous adverse reactions. Recently, topical tacalcitol has been shown to be effective in psoriasis. Objectives The aim of this open-label single-centre study is to investigate the efficacy and safety of high-concentration (20 μg g(-1)) tacalcitol ointment (Bonalfa-high (R), Teijin Pharma, Tokyo, Japan) in patients with facial psoriasis and to evaluate clinical response according to the distribution of facial psoriatic lesions. Patients and methods Thirty-seven patients were enrolled to this clinical trial. Tacalcitol 20 μg g(-1) ointment was applied once daily to psoriatic lesions of the face over an 8-week period. Patients were also categorized into three subtypes according to facial lesion distribution. Efficacy was evaluated by the facial Psoriasis Area and Severity Index (facial PASI) and the Physician`s Global Assessment (PGA) score at weeks 2, 4 and 8. The Subjective Global Assessment (SGA) was also determined at the end of the study. Results Thirty-three patients completed the clinical trial. Mean facial PASI of 33 patients at baseline was 9.58 and after 8 weeks of treatment the mean facial PASI decreased significantly to 3.88. By using PGA, patients showed the following responses to treatment: clearance (n = 1); excellent (6); good (16); fair (4); slight (5); no change (1). The response rate among the three facial psoriasis types showed no difference. Using the SGA, 27 (82%) of the patients presented excellent (15%) or good (67%) effect with tacalcitol 20 μg g(-1) ointment. No serious adverse reactions were observed. Conclusions This is the first clinical study reporting a relevant therapeutic effect and favourable safety profile of tacalcitol 20 μg g(-1) ointment in facial psoriasis. These results suggest that tacalcitol 20 μg g(-1) ointment can be used as the first-line treatment in patients with facial psoriasis. | ko_KR |
dc.description.sponsorship | This study was supported financially by Teijin
Pharma Co., Japan. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL | ko_KR |
dc.subject | facial psoriasis | ko_KR |
dc.subject | high-concentration tacalcitol | ko_KR |
dc.title | High-concentration (20 μg g−1) tacalcitol ointment in the treatment of facial psoriasis: an 8-week open-label clinical trial | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1111/j.1365-2133.2010.09758.x | - |
dc.citation.journaltitle | BRITISH JOURNAL OF DERMATOLOGY | - |
dc.description.citedreference | Woo SM, 2008, J AM ACAD DERMATOL, V58, P959, DOI 10.1016/j.jaad.2008.02.006 | - |
dc.description.citedreference | Yoon HS, 2008, BRIT J DERMATOL, V158, P1022, DOI 10.1111/j.1365-2133.2008.08495.x | - |
dc.description.citedreference | Canpolat F, 2008, EUR J DERMATOL, V18, P169, DOI 10.1684/ejd.2008.0363 | - |
dc.description.citedreference | Jacobi A, 2008, DERMATOLOGY, V216, P133, DOI 10.1159/000111510 | - |
dc.description.citedreference | Liao YH, 2007, BRIT J DERMATOL, V157, P1005, DOI 10.1111/j.1365-2133.2007.08201.x | - |
dc.description.citedreference | Lebwohl M, 2005, ARCH DERMATOL, V141, P1154 | - |
dc.description.citedreference | Bigby M, 2005, ARCH DERMATOL, V141, P1152 | - |
dc.description.citedreference | JO SJ, 2005, KOREAN J DERMATOL, V43, P1461 | - |
dc.description.citedreference | Park JY, 2004, J AM ACAD DERMATOL, V50, P582, DOI 10.1016/S0190-9622(03)02793-2 | - |
dc.description.citedreference | Ortonne JP, 2003, BRIT J DERMATOL, V148, P326 | - |
dc.description.citedreference | Katayama I, 2002, EUR J DERMATOL, V12, P553 | - |
dc.description.citedreference | Miyachi Y, 2002, EUR J DERMATOL, V12, P463 | - |
dc.description.citedreference | van de Kerkhof PCM, 2002, BRIT J DERMATOL, V146, P414 | - |
dc.description.citedreference | Schlotmann K, 2000, CONTACT DERMATITIS, V42, P260 | - |
dc.description.citedreference | Peters DC, 1997, DRUGS, V54, P265 | - |
dc.description.citedreference | VandeKerkhof PCM, 1996, BRIT J DERMATOL, V135, P758 | - |
dc.description.citedreference | Sato H, 1996, ARCH DERMATOL RES, V288, P656 | - |
dc.description.citedreference | BOUILLON R, 1995, EUR J ENDOCRINOL, V133, P7 | - |
dc.description.citedreference | GERRITSEN MJP, 1994, BRIT J DERMATOL, V131, P57 | - |
dc.description.citedreference | NISHIMURA M, 1994, ACTA DERM-VENEREOL, V186, P166 | - |
dc.description.citedreference | MILLS CM, 1993, CURR PROBL DERMATOL, V21, P122 | - |
dc.description.citedreference | MENNE T, 1992, SEMIN DERMATOL, V11, P278 | - |
dc.description.citedreference | BERNHARD JD, 1985, CLIN EXP DERMATOL, V10, P500 | - |
dc.description.citedreference | HARRISON PV, 1985, CLIN EXP DERMATOL, V10, P41 | - |
dc.description.citedreference | BERNHARD JD, 1983, INT J DERMATOL, V22, P291 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.